98%
921
2 minutes
20
Objective: To identify the rates and possible predictors of alcohol withdrawal syndrome (AWS) among adult trauma patients.
Methods: This is a retrospective review of all adult patients (18 years or older) included in the 2017 and 2018 American College of Surgeons Trauma Quality Program Participant User File (PUF). The main outcomes were rates and predictors of AWS.
Results: 1 677 351 adult patients were included in the analysis. AWS was reported in 11 056 (0.7%). The rate increased to 0.9% in patients admitted for more than 2 days and 1.1% in those admitted for more than 3 days. Patients with AWS were more likely to be male (82.7% vs. 60.7%, p<0.001), have a history of alcohol use disorder (AUD) (70.3% vs. 5.6%, p<0.001) and have a positive blood alcohol concentration (BAC) on admission (68.2% vs. 28.6%, p<0.001). In a multivariable logistic regression, history of AUD (OR 12.9, 95% CI 12.1 to 13.7), cirrhosis (OR 2.1, 95% CI 1.9 to 2.3), positive toxicology screen for barbiturates (OR 2.1, 95% CI 1.6 to 2.7), tricyclic antidepressants (OR 2.2, 95% CI 1.5 to 3.1) or alcohol (OR 2.5, 95% CI 2.4 to 2.7), and Abbreviated Injury Scale head score of ≥3 (OR 1.7, 95% CI 1.6 to 1.8) were the strongest predictors for AWS. Conversely, only 2.7% of patients with a positive BAC on admission, 7.6% with a history of AUD and 4.9% with cirrhosis developed AWS.
Conclusion: AWS after trauma was an uncommon occurrence in the patients in the PUF, even in higher-risk patient populations.
Level Of Evidence: IV: retrospective study with more than one negative criterion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175962 | PMC |
http://dx.doi.org/10.1136/tsaco-2022-001047 | DOI Listing |
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFBehav Brain Res
September 2025
Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, MS 441 002, India. Electronic address:
Alcohol Use Disorder (AUD) is a major global health challenge characterized by the recurrence of alcohol consumption, withdrawal symptoms, and significant social, economic, and health-related burdens. Despite conventional treatments such as cognitive behavioral therapy and medications like disulfiram and naltrexone, the majority of patients do not achieve adequate relief due to the multifactorial nature of this disorder, including mental health issues and neuroadaptive changes. Recent studies demonstrated that chronic alcohol consumption results in the disruption of both the production and signaling of endogenous agmatine, a neuromodulator synthesized from L-arginine.
View Article and Find Full Text PDFClin Drug Investig
September 2025
Department of Epidemiology, Biostatistics, Occupational Health, McGill University, Montreal, QC, Canada.
Background And Objectives: Benzodiazepines are commonly prescribed medications approved for and used in the treatment of anxiolytic and sleep disorders, as well as for seizures, and alcohol withdrawal. However, benzodiazepines are also controlled substances because of their potential for abuse and personal harm, which are especially prevalent among older people. It is therefore important to understand how benzodiazepines are being prescribed, and the prevalence of off-label benzodiazepine prescribing, of which very little is known because of challenges in documenting treatment indication.
View Article and Find Full Text PDFAlcohol
September 2025
School of Neuroscience, Virginia Polytechnic and State University, 970 Washington Street SW, Blacksburg, VA, 24061, USA. Electronic address:
Alcohol Use Disorder (AUD) affects millions of people globally and is characterized by cycles of intoxication, withdrawal, and relapse. Convergent clinical and preclinical evidence strongly support the conclusion that AUD precipitates chronic pain marked by mechanical and thermal hypersensitivity, yet currently available FDA-approved therapeutics do not effectively manage AUD-associated pain. This review synthesizes clinical and preclinical evidence on AUD-associated pain, highlighting known phenomena of allodynia and hyperalgesia as well as small and/or large fiber neuropathy in patient subpopulations along with preclinical acute and chronic alcohol exposure paradigm-specific nociceptive phenotypes in rodents.
View Article and Find Full Text PDFJ Neural Transm (Vienna)
September 2025
University Department of Psychiatry and Psychotherapy, Brandenburg Medical School, Immanuel Klinik Rüdersdorf, 15562, Rüdersdorf, Germany.
Alcohol use disorder (AUD) is a mental disorder with a high prevalence and is one of the most common diagnoses requiring inpatient treatment. For the pharmacological management of withdrawal and detoxification, tranquilizing and anticonvulsant drugs, as well as symptom-triggered therapy, are recommended. In this study, we investigated the use of psychotropic drugs in the inpatient treatment of patients with AUD or acute intoxication by analyzing data from the Drug Safety Program in Psychiatry (German: Arzneimittelsicherheit in der Psychiatrie; AMSP).
View Article and Find Full Text PDF